iPSC-derived Primary Cells: Expand Your Cell-based Assays With an Unlimited, Biologically Relevant SourceJun 27, 2019 at 12:00 PM ET
Toxicology and cancer researchers alike are challenged by the lack of a consistent source of cells with high physiological relevance for their cell-based assays. The source tissue for primary cells comes from a variety of donors, which can introduce interexperimental variability and confound experimental results. Differentiated induced pluripotent stem cell (iPSC)-derived cells fulfill the need for a consistent source of cells and physiological relevance. iPSCs are able to be generated in large cell numbers from a single clone, providing the needed consistency. Further, iPSCs can be differentiated into a variety of desired, functional cell types, affording the necessary biological relevance. Here we provide data demonstrating how differentiated iPSC-derived cells can be incorporated into immunoassays or further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.
- Differentiated iPSCs lend the ability to run large toxicity studies and drug screens on highly biologically relevant cells.
- ATCC iPSCs were used as the source for three types of differentiated cells: CD34+ progenitors, mesenchymal stem cells (MSCs), and monocytes.
- ATCC R&D scientists have generated in-depth data showing the iPSC-derived cells can be incorporated into immunoassays and further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.
Yalin Firinci, MBA
Product Line Business Specialist, ATCC
Yalin Firinci, M.B.A., works in product line business management with a focus on stem cells, immortalized primary cells, induced pluripotent stem cell-derived cells, and classical cell culture product lines. Previously he worked as a life science consultant at Avalere Health, a project manager at BioReliance, and interned as an API supply chain specialist at Pfizer. Yalin received a B.S. in Biology and an M.B.A. focusing on Finance from The George Washington University.